PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449/PTO Complete if known **Application Number** 09/747,521 INFORMATION DISCLOSURE 12/21/2000 Filing Date First Named Inventor STATEMENT BY APPLICATION Galloway Art Unit 1645 Examiner's Name Patricia Ann Duffy (Use as many sheets as necessary) 22727/04079 **Attorney Docket Number** of Sheet

Commission	Ciac	Document Number	Publication Date		Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No. 1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		plicant of Cited Document	Where Relevant Passage or Relevant Figures Appe	28
				+-			
							_
					·		_
	1			-			
	<u> </u>	·		+			-
	<u> </u>						
	<del> </del> -			+			
							_
	<del> </del>						_
		FORE	IGN PATENT DOCU	MENTS	6		
	T	Foreign Patent Document	Publication			Pages, Columns, Lines,	Γ
xaminer Initials*	Cite No. 1		MM-DD-Y		Name of Patentee or Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	
PD		WO 99/50439	10/07/99		Duesbery et al.		
PD		WO 92/19720	11/12/92		Mock et al.		-
							+

Examiner	/- · · · · - · · · ·	Date	
Signature	/Patricia Duffy/	Considered	06/01/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitut for form 1449/PTO Complete if known **Application Number** 09/747,521 INFORMATION DISCLOSURE Filing Date 12/21/2000 STATEMENT BY APPLICATION First Named Inventor Galloway Art Unit 1645 Examiner's Name (Use as many sheets as necessary) Patricia Ann Duffy Sheet of Attorney Docket Number 22727/04079

MAR 8 1 2006

		NON PATENT LITERATURE DOCUMENTS	
Initials* No. 1 the item (book, magazine, journal, serial, sy		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
PD		BROSSIER, "Functional analysis of the carboxy-terminal domain of bacillus anthracis protective antigen," <u>Infection and Immunity</u> (Feb. 1999) vol. 67, no. 2, pp 964-967.	
PD		FENG, et al., "P55, an Immunogenic but nonprotective 55-Kilodalton Borrelia burgdorferi Protein in murine lyme disease," <u>Infect. Immun.</u> (1996) Volume 64, No. 1, pages 363-365.	, , , , , , , , , , , , , , , , , , ,
PD		HAMMOND, et al., "Lethal factor active-site mutations affect catalytic activity in vitro," <u>Infection and Immunity</u> , (May 1998), vol. 66, no. 5, pp 2374-2378.	
PD		HERBERT, et al. "The Dictionary of Immunology", Academic Press (1995).	
PD		HOUGHTEN, et al., "Relative importance of position and individual amino acid residues in peptide antigen-antibody interactions: implications in the mechanism of antigenic drift and antigenic shift," <u>Vaccines</u> (1986) Volume 86, pages 21-25.	
PD	·	MCGUINNESS, et al., "Class 1 outer membrane protein of Neisseria meningitidis: epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology," Mol. Microbiol. (1993) Volume 7, pages 505-514.	
PD		MCGUINNESS, et al., "Point mutation in meningococcal por A gene associated with increased endemic disease," The Lancet (1991) Volume 337, pages 514-517.	
PD		PRICE, et al., "Genetic diversity in the protective antigen gene of bacillus anthracis," <u>Journal of Bacteriology</u> , (Apr. 1999), vol. 181, no. 8, pp. 2358-2362	
PD		ROTHEL, et al., "Sequential nucleic acid and recombinant adenovirus vaccination induces host-protective immune responses against Taenia ovis infection in sheep," <u>Parasite Immun.</u> (1997) Volume 19, pages 221-227.	

Examiner	(Data da Da Cont	Date	06/01/2006
Signature	/Patricia Duffy/	Considered	06/01/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute (6)	form 1449/PTO			Complete if known		
			_	Application Number	09/747,521	
INFORMATION DISCLOSURE				Filing Date	12/21/2000	
STATEMENT BY APPLICATION			ICATION	First Named Inventor	Galloway	
				Art Unit	1645	
(Us	e as many sheets	as ne	cessary)	Examiner's Name	Patricia Ann Duffy	
Sheet	3	of	3	Attorney Docket Number	22727/04079	

PD		TONELLO, et al. "Tyrosine-728 and glutamic acid-735 are essential for the metalloproteolytic activity of the lethal factor of bacillus anthracis," <u>Biochemical and Biophysical Research Communications</u> , 313 (2004) pp 496-502.	
PD		VARUGHESE, et al. "Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin," <u>Infection and Immunity</u> , (Apr. 1999) vol. 67, no. 4, pp 1860-1865.	·
	·		

06/01/2006

Examiner	/Patricia Duffy/	Date	06/01/2006
Signature	/ Facilitia Dully/	Considered	30, 52, 2005

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2006 OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Complete if known		
				Application Number	09/747,521	
INFORM.	ATION DIS	CLC	SURE	Filing Date	12/21/2000	
STATEMENT BY APPLICATION			ICATION	First Named Inventor	Galloway	
				Art Unit	1645	
(Use as many sheets as necessary)				Examiner's Name	Patricia A. Duffy	
Sheet	1 1	of	1	Attorney Docket Number	22727/04079	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-lssue number(s), publisher, city and/or country where published				
1		MAHLANDT, et al., "Technical Manuscript 229", Army Biological Labs			
PD		Frederick MD (1965), pages 1-23.	•		
		02/12/2007			
	}				
			<u> </u>		

Examiner	(	Date	02/12/2027
Signature	/Patricia Duffy/	Considered	02/12/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.